EVOTEC SE - SPON ADR (EVO) Fundamental Analysis & Valuation

NASDAQ:EVO • US30050E1055

Current stock price

2.7 USD
+0.12 (+4.65%)
Last:

This EVO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. EVO Profitability Analysis

1.1 Basic Checks

  • In the past year EVO has reported negative net income.
  • EVO had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: EVO reported negative net income in multiple years.
  • In the past 5 years EVO always reported a positive cash flow from operatings.
EVO Yearly Net Income VS EBIT VS OCF VS FCFEVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

  • EVO has a Return On Assets (-8.97%) which is in line with its industry peers.
  • Looking at the Return On Equity, with a value of -19.87%, EVO is in line with its industry, outperforming 49.12% of the companies in the same industry.
Industry RankSector Rank
ROA -8.97%
ROE -19.87%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
EVO Yearly ROA, ROE, ROICEVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

  • The Gross Margin of EVO (10.82%) is worse than 89.47% of its industry peers.
  • EVO's Gross Margin has declined in the last couple of years.
  • EVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
EVO Yearly Profit, Operating, Gross MarginsEVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. EVO Health Analysis

2.1 Basic Checks

  • EVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for EVO has been increased compared to 1 year ago.
  • The number of shares outstanding for EVO has been increased compared to 5 years ago.
  • EVO has a better debt/assets ratio than last year.
EVO Yearly Shares OutstandingEVO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EVO Yearly Total Debt VS Total AssetsEVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of 0.39, we must say that EVO is in the distress zone and has some risk of bankruptcy.
  • EVO's Altman-Z score of 0.39 is on the low side compared to the rest of the industry. EVO is outperformed by 64.91% of its industry peers.
  • A Debt/Equity ratio of 0.48 indicates that EVO is not too dependend on debt financing.
  • EVO has a Debt to Equity ratio (0.48) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z 0.39
ROIC/WACCN/A
WACC7.26%
EVO Yearly LT Debt VS Equity VS FCFEVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • EVO has a Current Ratio of 2.12. This indicates that EVO is financially healthy and has no problem in meeting its short term obligations.
  • EVO has a Current ratio of 2.12. This is comparable to the rest of the industry: EVO outperforms 42.11% of its industry peers.
  • EVO has a Quick Ratio of 2.03. This indicates that EVO is financially healthy and has no problem in meeting its short term obligations.
  • EVO has a Quick ratio (2.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 2.03
EVO Yearly Current Assets VS Current LiabilitesEVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. EVO Growth Analysis

3.1 Past

  • EVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.17%.
  • The Revenue has decreased by -2.67% in the past year.
  • EVO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.29% yearly.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%

3.2 Future

  • EVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.42% yearly.
  • The Revenue is expected to grow by 5.29% on average over the next years.
EPS Next Y62.82%
EPS Next 2Y35.95%
EPS Next 3Y27.94%
EPS Next 5Y18.42%
Revenue Next Year-1.62%
Revenue Next 2Y-0.7%
Revenue Next 3Y3.15%
Revenue Next 5Y5.29%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EVO Yearly Revenue VS EstimatesEVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
EVO Yearly EPS VS EstimatesEVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. EVO Valuation Analysis

4.1 Price/Earnings Ratio

  • EVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year EVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVO Price Earnings VS Forward Price EarningsEVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

  • EVO's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 523.09
EVO Per share dataEVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EVO's earnings are expected to grow with 27.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.95%
EPS Next 3Y27.94%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EVO Dividend Analysis

5.1 Amount

  • No dividends for EVO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EVO Fundamentals: All Metrics, Ratios and Statistics

EVOTEC SE - SPON ADR

NASDAQ:EVO (4/8/2026, 1:06:33 PM)

2.7

+0.12 (+4.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05
Earnings (Next)N/A
Inst Owners58.89%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap959.83M
Revenue(TTM)756.33M
Net Income(TTM)-158.98M
Analysts76.92
Price Target5.27 (95.19%)
Short Float %0.13%
Short Ratio2.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.59%
Min EPS beat(2)-21.86%
Max EPS beat(2)-3.31%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.97%
Min Revenue beat(2)-9.17%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.99%
Min Revenue beat(4)-9.17%
Max Revenue beat(4)-0.93%
Revenue beat(8)1
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)1.12%
Revenue beat(16)7
Avg Revenue beat(16)2.95%
PT rev (1m)0%
PT rev (3m)1.83%
EPS NQ rev (1m)10.59%
EPS NQ rev (3m)62.98%
EPS NY rev (1m)0.11%
EPS NY rev (3m)2.16%
Revenue NQ rev (1m)1.68%
Revenue NQ rev (3m)3.49%
Revenue NY rev (1m)1.29%
Revenue NY rev (3m)1.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.1
P/FCF N/A
P/OCF 589.02
P/B 1.04
P/tB 1.66
EV/EBITDA 523.09
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)0
OCFY0.17%
SpS2.46
BVpS2.6
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.97%
ROE -19.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.82%
FCFM N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA 209.82
Cap/Depr 90.72%
Cap/Sales 12.19%
Interest Coverage N/A
Cash Conversion 76.3%
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 2.03
Altman-Z 0.39
F-Score4
WACC7.26%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y62.82%
EPS Next 2Y35.95%
EPS Next 3Y27.94%
EPS Next 5Y18.42%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
Revenue Next Year-1.62%
Revenue Next 2Y-0.7%
Revenue Next 3Y3.15%
Revenue Next 5Y5.29%
EBIT growth 1Y-6.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.95%
EBIT Next 3Y47.8%
EBIT Next 5Y33.1%
FCF growth 1Y52.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y107.69%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%

EVOTEC SE - SPON ADR / EVO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EVOTEC SE - SPON ADR?

ChartMill assigns a fundamental rating of 2 / 10 to EVO.


Can you provide the valuation status for EVOTEC SE - SPON ADR?

ChartMill assigns a valuation rating of 1 / 10 to EVOTEC SE - SPON ADR (EVO). This can be considered as Overvalued.


Can you provide the profitability details for EVOTEC SE - SPON ADR?

EVOTEC SE - SPON ADR (EVO) has a profitability rating of 2 / 10.